Linden Capital raises $750M fund; J&J, others hit with contact lens price-fixing lawsuit;

@FierceMedDev: Micro-cap TearLab gets $35M in debt to get to breakeven on dry eye test . More | Follow @FierceMedDev

@VarunSaxena2: @AdvaMedUpdate calls for more appropriate medical device reimbursement in Japan - FierceMedicalDevices. Story | Follow @VarunSaxena2

@EmilyWFierce: OpGen eyes IPO worth up to $37M for drug-resistant bacteria genetic Dx. FierceDiagnostics article | Follow @EmilyWFierce

> Linden Capital Partners has closed an oversubscribed $750 million fund to invest in mid-market healthcare and life sciences companies. More

> Chicago-based healthcare incubator Matter added 10 more startups including Briteseed, which integrates biosensors into minimally invasive surgical tools; surgeon-backed device and app developer Jacobson Medical Services; and Pathfinder Software, which develops software to connect medical devices and wearable sensors with mobile, cloud computing and clinical systems. Blog

> Johnson & Johnson's ($JNJ) Alcon Laboratories and other contact lens manufacturers are targeted in a class action lawsuit in a California court that they illegally controlled prices on contact lenses sold at Wal-Mart ($WMT) and other major retailers. More (reg. req.)

> A new wearable from startup Skulpt measures the quality of muscle fibers and the amount of fat on a person's body. Story

Biotech News

@FierceBiotech: Biotech upstart Tricida banks $30M for its kidney drug with OrbiMed in tow. Story | Follow @FierceBiotech

@JohnCFierce: Interested in Asian biopharma? Get the latest from @FiercePharmAsia. Newsletter | Follow @JohnCFierce

@DamianFierce: Via @Reuters, it's March 5 and biopharma deal dollars have already topped 2011. Article | Follow @DamianFierce

> Surprised, stunned and supportive: Analysts assess AbbVie's $21B Pharmacyclics deal. Editor's Corner

> Summit pulls off a downsized IPO for its DMD drug. Story

Pharma News

@FiercePharma: #ICYMI yesterday: $BMY leapfrogs Merck with Opdivo approval in lung cancer. Story | Follow @FiercePharma

@EricPFierce: MS Pharma in Jordan gets $30M development loan to expand its drug manufacturing. News | Follow @EricPFierce

@CarlyHFierce: J&J, Merck to advance #Ebola vaccines in Africa, but their fate rests in WHO's hands. More | Follow @CarlyHFierce

> Mallinckrodt ponies up $2.3B for Ikaria and its neonatal respiratory med. Article

> Oregon, Illinois join state crusade to limit patient copays. Story

Pharma Asia News

> Major policy shift on costs and safety views as China moves to lift price controls on drugs. News

> Denovo Biopharma eyes China trial of licensed Eli Lilly neuroscience drug. Article

> Indonesia gains momentum as drug firms eye second year of phased national insurance. Item

> Big Pharma bodies ask China FDA to review comparability in biosimilar approval guidelines. More

> Hutchison China MediTech eyes first modern drug approval in China next year with Eli Lilly candidate. Report

Vaccines News

> Pfizer scores new Prevenar indication in Europe. Article

> Bristol-Myers bets $1B on Bavarian Nordic cancer vaccine. News

> J&J, Merck to advance Ebola vaccines in Africa, but their fate rests in WHO's hands. Story

> With 77 layoffs, Valeant gets to work squeezing costs from Dendreon. Item

> Aduro, BMS cancer vaccine combo to start Phase II. Report

Pharma Manufacturing News

> FDA aims to disseminate drug shortage info through app. More

> Generic drugmaker snaps up Lockheed site with big expansion plans. Article

> Jordan's MS Pharma gets $30M to expand manufacturing there. Report

> FDA campaign against use of foreign-made cancer drugs rolls up another doctor. Story

> Patheon buys specialty API maker IRIX. News

And Finally... CSL Plasma will use the Haemonetics ($HAE) software to manage plasma collection at its more than 100 plasma donation centers across the U.S. and Europe. Release

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.